Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Content from other channels on our network

EPOC Enviro secures patent for PFAS remediation technology

NSW passes legislation to mandate battery recycling

Climate Council rates political parties on climate

Boral secures grant for cement kiln carbon reduction

Vast secures grant to progress SA Solar Fuels project

Permanent identification to follow proven sexual misconduct

Man charged over alleged antisemitic incident in hospital lift

Medical logistics provider gains on-brand hi-vis workwear

Western Sydney Local Health District prosecution withdrawn

Bankstown-Lidcombe and Liverpool Hospitals trial body cameras

Food industry and goverment repond to US tariff imposition

Getting the right texture: toolkit to help create more appealing food

A message from a sponsor of FoodTech Qld

Matthews' stand offering deep 2D barcoding intel at FoodTech Qld

Aranet supermarket temperature monitoring solution